Brief: Processa Pharmaceuticals Provides Interim Analysis From Ongoing Phase 1B Trial Of Next Generation Capecitabine Showing Improved Safety Over Capecitabine

Processa Pharmaceuticals

19/12/2023 14:05

Dec 19 (Reuters) - Processa Pharmaceuticals Inc
 PCSA.O :
    * PROCESSA PHARMACEUTICALS PROVIDES INTERIM ANALYSIS FROM
ONGOING
PHASE 1B TRIAL OF NEXT GENERATION CAPECITABINE SHOWING IMPROVED
SAFETY OVER CAPECITABINE
    * PROCESSA PHARMACEUTICALS:  INTERIM ANALYSIS OF NGC-CAP
PHASE 1B
DATA SHOWS IMPROVED SAFETY

Source text for Eikon:  ID:nGNX3H1fZY 
Further company coverage:  PCSA.O 

 ((Reuters.Briefs@thomsonreuters.com;))